J. Jefferson Smith - 01 Jun 2026 Form 4 Insider Report for PRECISION BIOSCIENCES INC (DTIL)

Reporting relationship: Chief Research Officer
Issuer ticker: DTIL
Reported as of: 01 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2026, 16:06:39 UTC
Prior SEC filing: 19 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ John Alexander Kelly, Attorney-in-Fact for J. Jefferson Smith

Key filing fact

J. Jefferson Smith filed Form 4 for PRECISION BIOSCIENCES INC (DTIL) on 03 Jun 2026.

Key facts

This page summarizes J. Jefferson Smith's Form 4 filing for PRECISION BIOSCIENCES INC (DTIL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2026, 16:06.

Change

Previous filing in this sequence was filed on 19 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001770169 Primary reporting owner

SMITH J. JEFFERSON

Relationship: Chief Research Officer
Address: C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM
Signature: /s/ John Alexander Kelly, Attorney-in-Fact for J. Jefferson Smith
Signature date: 03 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DTIL transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +57,389
Change %
Price: $0.000000^*
Shares after: 57,389
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 57,389
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F2

Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.